To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Prior treatment

• 1\. Invasive bladder cancer (T2 and above) and / or with regional lymph node and distant metastasis.
  • 2\. Combined urothelial carcinoma outside the bladder (i. e., urethra, ureter or renal pelvis).
  • 3\. Any other antitumor therapy received within 4 weeks before study administration, .
  • 4 Subjects plan to undergo major surgery during the study or within 4 weeks before the first dose.
  • 5, Known allergic to DV and its components or to any excipients.

• Voluntary consent to participate in the study and signed the informed consent form.
• Male or female, age 18-75 years (including both).
• Histologic confirmed non-muscle invasive bladder urothelial carcinoma (NMIBC), and the risk group met the high-risk (including very high-risk) group.
  • Note: High-risk NMIBC is a high-grade / G3 tumor meeting any of the following:
  • a.Carcinoma in situ (CIS) b. T1 stage c. diameter\>3cm d.Multiple tumors, or recurrent tumors.
• Absence of resectable disease（Ta and/or T1 disease） after transurethral resection (TURBT) procedures (residual CIS acceptable;
• The urologist assessed that radical surgery for bladder cancer was not suitable or the subject refused radical surgery for bladder cancer.
• Tumor tissue samples were detected by immunohistochemistry (IHC) to satisfy HER2 expression of 1+, 2+ or 3+.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Adequate heart, bone marrow, liver, kidney and coagulation function